UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
-
Recruiting
- Pediatrics
- On Hold
Conditions
Glioma
Glioblastoma
This phase II/III clinical trial is a response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed and recurrent GBM.
Conditions
Meningioma
This single center pilot trial is designed to demonstrate the safety of adjuvant hypofractionated stereotactic radiosurgery for patients after gross total of resection of intermediate risk meningioma.
Conditions
Glioma
Astrocytoma
Glioblastoma
This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in patients with newly diagnosed high grade glioma.
Conditions
Medulloblastoma
This is a phase 2 clinical trial that will evaluate the efficacy of difluoromethylornithine (DFMO) as a single agent against molecular high risk and very high risk medulloblastoma as well relapsed/refractory medulloblastoma.
Conditions
Glioma
This project will use cutting-edge epigenomic science to develop and validate a new generation of immune biomarkers to improve glioma survival prognostication and will provide clinically applicable tools to identify tumor IDH status prior to surgical intervention and evaluate the effects of radiation and immunotherapy.
Conditions
Medulloblastoma
The study will use a new treatment approach based on the molecular characteristics of each participant’s tumor by testing the feasibility of performing real-time drug screening on tissue taken during surgery, and of having a specialized tumor board assign a treatment plan based on the results of this screening and genomic sequencing.
Conditions
Meningioma
This study aims to better understand the challenges and symptoms that meningioma survivors are living with to improve treatment strategies and follow-up care for with patients with meningioma.
Conditions
Glioma
Glioblastoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Oligodendroglioma
This non-therapeutic study aims to collect prospective neurocognitive and imaging data before, during, and after surgery.
Conditions
Neurofibromatosis type 1
Children with NF1 are at increased risk of developing low- and high-grade gliomas. Up to one-third of NF1-associated low-grade glioma (LGG) occurs extrinsic to the optic pathway.
Conditions
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Brainstem Glioma
Diffuse Midline Glioma
Medulloblastoma
Choroid Plexus Tumors
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
The purpose is to evaluate cognitive, social, emotional, and behavioral functioning over time in patients already enrolled in a Children’s Oncology Group Phase III clinical trial.
Conditions
Craniopharyngioma
This phase II trial will assess the tolerability and efficacy of combination therapy with PD-1 (nivolumab) and pan-RAF-kinase (DAY101) inhibition for the treatment of children and young adults with craniopharyngioma.
Conditions
Diffuse Midline Glioma
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Glioblastoma
Brainstem Glioma
Ependymoma
This phase I clinical trial will evaluate ONC206 alone or in combination with radiation therapy in treating pediatric patients with newly diagnosed or recurrent DMGs, or other recurrent primary malignant brain tumors.